{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-274192","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.614885+00:00","generated_at":"2026-05-16T22:50:28.192757+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroGen Q3 2025: Net loss $13.1M, China sale ~$220M, cash $121.1M into 2028","bullets":["Net loss from continuing ops $13.1M ($3.25 loss per share) vs $48.3M ($12.01 loss) YoY.","Total revenue from continuing ops $1.1M, up from $0.1M YoY.","Completed sale of FibroGen China to AstraZeneca for ~$220M ($85M enterprise + $135M net cash).","Cash, equivalents, receivables, and investments $121.1M; cash runway into 2028; repaid Morgan Stanley term loan.","Initiated Phase 2 trial of FG-3246 in mCRPC; FDA agreed on Phase 3 roxadustat design for LR-MDS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-274192","json":"https://secwatch.observer/filing/0001193125-25-274192.json","markdown":"https://secwatch.observer/filing/0001193125-25-274192.md","text":"https://secwatch.observer/filing/0001193125-25-274192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/0001193125-25-274192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000119312525274192/fgen-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:50:28.192757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}